MeSH D006261 - headache
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Aspirin, Caffeine, Butalbital | Butalbital, Aspirin Caffeine |  | 1984-10-31 |  |  |
| Naproxen | Naproxen |  | 1995-02-28 |  |  | |
| Novast Laboratories | Acetaminophen, Caffeine, Butalbital | Butalbital, Acetaminophen Caffeine |  | 2021-11-17 |  |  |
| Taro Pharmaceutical | Acetaminophen, Caffeine, Butalbital | Butalbital, Acetaminophen Caffeine |  | 2020-07-01 |  |  |
| Glenmark Pharmaceuticals | Naproxen | Naproxen |  | 2007-03-28 |  |  |
| Mylan | Doxylamine, Pyridoxine | Doxylamine Pyridoxine |  | 2020-07-06 |  |  |
| Naproxen | Naproxen |  | 1993-12-21 |  |  | |
| Naproxen, Esomeprazole strontium | Naproxen Esomeprazole Magnesium |  | 2021-07-20 |  |  | |
| Perrigo | Naproxen | Naproxen |  | 1997-01-13 |  |  |
| Naproxen, Diphenhydramine | Naproxen Diphenhydramine |  | 2019-05-10 |  |  | |
| Pseudoephedrine, Naproxen | Naproxen Pseudoephedrine |  | 2004-03-17 |  |  | |
| P&L Developments (PLD) | Naproxen, Diphenhydramine | Naproxen Diphenhydramine |  | 2019-01-25 |  |  |
| Cipla | Naproxen | Naproxen |  | 2011-08-24 |  |  |
| Sandoz | Aspirin, Meprobamate | Mepro-aspirin |  | 1987-03-02 |  |  |
| Naproxen | Naproxen |  | 1993-12-21 |  |  | |
| Aspirin, Caffeine, Butalbital | Lanorinal |  | 1985-10-11 |  |  | |
| Novartis | Acetylcholine | Miochol |  | 1982-01-01 |  |  |
1
2
3
4
5
6
...
9
>
Clinical Trials
Historical Success Rate
Phase 1
84%16/19
Phase 2
69%9/13
Phase 3
67%34/51
Approved: 6Overall Success rate: 39%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use